Table 1.
Updated version of the nomenclature of G1e variants of IgG1, with a focus on silent (blue highlighting 1) and boosted antibodies (red highlighting 1), and immunostimulatory antibodies highlighted in capital letters.
| Ge Numbering |
Heavy Chain Variations (EU Numbering) 2 | INN (Year of First Approval in the EU, USA or JP) |
|---|---|---|
| G1e0 | No variation | Many examples, notably: IPILIMUMAB (2011), AVELUMAB (2017) |
| G1e1 |
Lacks CH1 +
C220S C226S C229S P238S substitutions |
abatacept (2005), belatacept (2011) |
| G1e2 |
Lacks CH1 +
Production in E.coli (aglycosylation) |
romiplostim (2008) |
| G1e3 | Lack CH1 + Deletion of the five first amino acids of the hinge region |
aflibercept (2011), efmoroctocog α (2014), eftrenonacog α (2014) |
| G1e4 | Hypo- or afucosylation | mogamulizumab (2012), benralizumab (2017), naxitamab (2021), inebilizumab (2022) |
| G1e5 |
Addition of a bisecting GlcNAc
also indirectly inducing hypo- or afucosylation |
obinutuzumab (2013) |
| G1e6 | F126L substitution | ramucirumab (2014), necitumumab (2015) |
| G1e7 | L235A G237A substitutions | vedolizumab (2014) |
| G1e8 | N297A substitution | ATEZOLIZUMAB (2016) |
| G1e9 | L234F L235E P331S substitutions | DURVALUMAB (2017) |
| G1e10 | L234A L235A substitutions | etesevimab (2021), risankizumab (2019) |
| G1e11 | K213A N297A substitutions | eptinezumab (2020) |
| G1e12 | S239D K274Q Y296F Y300F L309V I332E A339T V397M substitutions | tafasitamab (2020) |
| G1e13 | L235V F243L R292P Y300L P396L substitutions | margetuximab (2020) |
| G1e14 | F405L substitution and afucosylation | amivantamab chain A (2021) |
| K409R substitution and afucosylation | amivantamab chain B (2021) | |
| G1e15 | L234F L235E M252Y S254T T256E P331S substitutions | tixagevimab/cilgavimab (2021) |
| G1e16 | M428L N434S substitutions | sotrovimab (2021) |
| G1e17 | M252Y S254T T256E H433K N434F susbtitutions | efgartigimod (2021) |
| G1e18 | N297G T366W substitutions (chain A) | mosunetuzumab (2022) |
| N297G T366S L368A Y407V substitutions (chain B) |
1 Variants devoid of effector functions are highlighted in blue, those boosted for their effector functions in red, those modified for increased half-life in yellow, those with both increased half-life and decreased effector functions therefore in green, those with not interfering Fc functions in grey. 2 The deliberated deletion of the C-terminal lysine (K447) is not included in this nomenclature.